Oxaliplatin-related neurotoxicity: is chelation the solution?

A De Gramont, A Cervantes, T Andre, A Figer, G Lledo, M Flesch, L Mineur, G Russ, E Quinaux, P-L Etienne, None, OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer Journal of Clinical Oncology. ,vol. 22, pp. 3525- 3525 ,(2004) , 10.1200/JCO.2004.22.90140.3525

Erick Gamelin, Laurence Gamelin, Laura Bossi, Stefan Quasthoff, Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures Seminars in Oncology. ,vol. 29, pp. 21- 33 ,(2002) , 10.1016/S0093-7754(02)90017-5

Jean Marc Extra, Marc Espie, Fabien Calvo, Christophe Ferme, Laurent Mignot, Michel Marty, Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. ,vol. 25, pp. 299- 303 ,(1990) , 10.1007/BF00684890

Laurence Gamelin, Michele Boisdron-Celle, Remy Delva, Véronique Guérin-Meyer, Norbert Ifrah, Alain Morel, Erick Gamelin, Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions: A Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and Leucovorin for Advanced Colorectal Cancer Clinical Cancer Research. ,vol. 10, pp. 4055- 4061 ,(2004) , 10.1158/1078-0432.CCR-03-0666

Thierry André, Corrado Boni, Lamia Mounedji-Boudiaf, Matilde Navarro, Josep Tabernero, Tamas Hickish, Clare Topham, Marta Zaninelli, Philip Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery de Gramont, None, Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer The New England Journal of Medicine. ,vol. 350, pp. 2343- 2351 ,(2004) , 10.1056/NEJMOA032709